uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands.
Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Hälsoekonomi. Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden.
Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
Vise andre og tillknytning
2016 (engelsk)Inngår i: The Pharmacogenomics Journal, ISSN 1470-269X, E-ISSN 1473-1150, Vol. 16, nr 5, s. 478-484Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden.

sted, utgiver, år, opplag, sider
2016. Vol. 16, nr 5, s. 478-484
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-297969DOI: 10.1038/tpj.2016.41ISI: 000384035000009PubMedID: 27272045OAI: oai:DiVA.org:uu-297969DiVA, id: diva2:944128
Forskningsfinansiär
EU, European Research Council, HEALTH-F2-2009-223062Swedish Society for Medical Research (SSMF)Swedish Heart Lung FoundationTilgjengelig fra: 2016-06-29 Laget: 2016-06-29 Sist oppdatert: 2017-11-28bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Langenskiöld, SophieWadelius, Mia

Søk i DiVA

Av forfatter/redaktør
Langenskiöld, SophieWadelius, Mia
Av organisasjonen
I samme tidsskrift
The Pharmacogenomics Journal

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 390 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf